Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Outset Medical adds Brent Lang to its board of directors

EditorNatashya Angelica
Published 03/13/2024, 04:21 PM
© Reuters
OM
-

SAN JOSE, Calif. - Outset Medical, Inc. (NASDAQ:OM), a company focused on innovating dialysis technology, has announced the appointment of Brent D. Lang to its board of directors. This strategic move comes as Outset continues to expand its market presence with its flagship Tablo Hemodialysis System.

Lang's extensive background in medical technology, including his recent tenure as Chairman and CEO of Vocera (NYSE:VCRA) Communications, positions him well to contribute to Outset's growth. His experience is expected to complement Outset's direction, particularly in software-enabled business models that align with the company's recurring revenue approach.

Leslie Trigg, Chair and CEO of Outset, expressed confidence in Lang's ability to contribute to the company's mission of improving patient lives through innovative healthcare solutions. "He is an ideal board member to help guide our continued growth," Trigg stated.

The appointment coincides with the departure of Katie M. Szyman from the Outset board, as she prepares to assume the role of CEO at a spinoff of Edwards Lifesciences’ Critical Care division. Trigg thanked Szyman for her contributions during a transformative phase for Outset, which included a public offering.

In his new role, Lang will also serve on the Audit Committee. His career highlights include leadership roles at Vocera Communications and positions with 3Com Corporation and Monitor Company, Inc. Lang also brings a unique perspective as a former Olympic gold medalist and a current chairman of Movella Holdings Inc. and a board member of Thriveworks.

"I look forward to joining such an accomplished board, and a company that is having a direct and profound impact on the lives of dialysis patients and providers," said Lang, recognizing Outset's potential for growth.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Outset's Tablo System is FDA cleared for use across various care settings, from hospitals to homes. It is designed to simplify the delivery of dialysis treatment by integrating water purification and on-demand dialysate production, effectively making it a mobile dialysis clinic. This technology, coupled with its data analytics platform, aims to enhance the overall dialysis care experience.

This news is based on a recent press release statement from Outset Medical, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.